Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges
Cheng-Mei Tian,1,2,* Yuan Zhang,3,* Mei-Feng Yang,4,* Hao-Ming Xu,5 Min-Zheng Zhu,6 Jun Yao,1 Li-Sheng Wang,1 Yu-Jie Liang,7 De-Feng Li1 1Department of Gastroenterology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Ho...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-05-01
|
| Series: | Journal of Inflammation Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/stem-cell-therapy-in-inflammatory-bowel-disease-a-review-of-achievemen-peer-reviewed-fulltext-article-JIR |
| _version_ | 1797825891082960896 |
|---|---|
| author | Tian CM Zhang Y Yang MF Xu HM Zhu MZ Yao J Wang LS Liang YJ Li DF |
| author_facet | Tian CM Zhang Y Yang MF Xu HM Zhu MZ Yao J Wang LS Liang YJ Li DF |
| author_sort | Tian CM |
| collection | DOAJ |
| description | Cheng-Mei Tian,1,2,* Yuan Zhang,3,* Mei-Feng Yang,4,* Hao-Ming Xu,5 Min-Zheng Zhu,6 Jun Yao,1 Li-Sheng Wang,1 Yu-Jie Liang,7 De-Feng Li1 1Department of Gastroenterology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, People’s Republic of China; 2Department of Emergency, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, People’s Republic of China; 3Department of Medical Administration, Huizhou Institute of Occupational Diseases Control and Prevention, Huizhou, Guangdong, People’s Republic of China; 4Department of Hematology, Yantian District People’s Hospital, Shenzhen, Guangdong, People’s Republic of China; 5Department of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, People’s Republic of China; 6Department of Gastroenterology and Hepatology, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, People’s Republic of China; 7Department of Child and Adolescent Psychiatry, Shenzhen Kangning Hospital, Shenzhen, Guangdong, People’s Republic of China*These authors contributed equally to this workCorrespondence: Li-Sheng Wang; De-Feng Li, Department of Gastroenterology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), No. 1017, Dongmen North Road, Luohu District, Shenzhen, 518020, People’s Republic of China, Tel +86 755 25533018, Email wanglsszrmyy@163.com; ldf830712@163.comAbstract: Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is a group of chronic inflammatory diseases of the gastrointestinal tract. Repeated inflammation can lead to complications, such as intestinal fistula, obstruction, perforation, and bleeding. Unfortunately, achieving durable remission and mucosal healing (MH) with current treatments is difficult. Stem cells (SCs) have the potential to modulate immunity, suppress inflammation, and have anti-apoptotic and pro-angiogenic effects, making them an ideal therapeutic strategy to target chronic inflammation and intestinal damage in IBD. In recent years, hematopoietic stem cells (HSCs) and adult mesenchymal stem cells (MSCs) have shown efficacy in treating IBD. In addition, numerous clinical trials have evaluated the efficiency of MSCs in treating the disease. This review summarizes the current research progress on the safety and efficacy of SC-based therapy for IBD in both preclinical models and clinical trials. We discuss potential mechanisms of SC therapy, including tissue repair, paracrine effects, and the promotion of angiogenesis, immune regulation, and anti-inflammatory effects. We also summarize current SC engineering strategies aimed at enhancing the immunosuppressive and regenerative capabilities of SCs for treating intestinal diseases. Additionally, we highlight current limitations and future perspectives of SC-related therapy for IBD.Graphic Abstract: Keywords: stem cells, mesenchymal stromal cells, HSCs, immunosuppression, inflammatory bowel disease, ulcerative colitis, Crohn’s disease |
| first_indexed | 2024-03-13T11:00:33Z |
| format | Article |
| id | doaj.art-8c64d673a7be4787b51f1d920725723a |
| institution | Directory Open Access Journal |
| issn | 1178-7031 |
| language | English |
| last_indexed | 2024-03-13T11:00:33Z |
| publishDate | 2023-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Inflammation Research |
| spelling | doaj.art-8c64d673a7be4787b51f1d920725723a2023-05-16T19:06:18ZengDove Medical PressJournal of Inflammation Research1178-70312023-05-01Volume 162089211983767Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and ChallengesTian CMZhang YYang MFXu HMZhu MZYao JWang LSLiang YJLi DFCheng-Mei Tian,1,2,* Yuan Zhang,3,* Mei-Feng Yang,4,* Hao-Ming Xu,5 Min-Zheng Zhu,6 Jun Yao,1 Li-Sheng Wang,1 Yu-Jie Liang,7 De-Feng Li1 1Department of Gastroenterology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, People’s Republic of China; 2Department of Emergency, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, People’s Republic of China; 3Department of Medical Administration, Huizhou Institute of Occupational Diseases Control and Prevention, Huizhou, Guangdong, People’s Republic of China; 4Department of Hematology, Yantian District People’s Hospital, Shenzhen, Guangdong, People’s Republic of China; 5Department of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, People’s Republic of China; 6Department of Gastroenterology and Hepatology, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, People’s Republic of China; 7Department of Child and Adolescent Psychiatry, Shenzhen Kangning Hospital, Shenzhen, Guangdong, People’s Republic of China*These authors contributed equally to this workCorrespondence: Li-Sheng Wang; De-Feng Li, Department of Gastroenterology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), No. 1017, Dongmen North Road, Luohu District, Shenzhen, 518020, People’s Republic of China, Tel +86 755 25533018, Email wanglsszrmyy@163.com; ldf830712@163.comAbstract: Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is a group of chronic inflammatory diseases of the gastrointestinal tract. Repeated inflammation can lead to complications, such as intestinal fistula, obstruction, perforation, and bleeding. Unfortunately, achieving durable remission and mucosal healing (MH) with current treatments is difficult. Stem cells (SCs) have the potential to modulate immunity, suppress inflammation, and have anti-apoptotic and pro-angiogenic effects, making them an ideal therapeutic strategy to target chronic inflammation and intestinal damage in IBD. In recent years, hematopoietic stem cells (HSCs) and adult mesenchymal stem cells (MSCs) have shown efficacy in treating IBD. In addition, numerous clinical trials have evaluated the efficiency of MSCs in treating the disease. This review summarizes the current research progress on the safety and efficacy of SC-based therapy for IBD in both preclinical models and clinical trials. We discuss potential mechanisms of SC therapy, including tissue repair, paracrine effects, and the promotion of angiogenesis, immune regulation, and anti-inflammatory effects. We also summarize current SC engineering strategies aimed at enhancing the immunosuppressive and regenerative capabilities of SCs for treating intestinal diseases. Additionally, we highlight current limitations and future perspectives of SC-related therapy for IBD.Graphic Abstract: Keywords: stem cells, mesenchymal stromal cells, HSCs, immunosuppression, inflammatory bowel disease, ulcerative colitis, Crohn’s diseasehttps://www.dovepress.com/stem-cell-therapy-in-inflammatory-bowel-disease-a-review-of-achievemen-peer-reviewed-fulltext-article-JIRstem cellsmesenchymal stromal cellshscsimmunosuppressioninflammatory bowel diseaseulcerative colitiscrohn's disease |
| spellingShingle | Tian CM Zhang Y Yang MF Xu HM Zhu MZ Yao J Wang LS Liang YJ Li DF Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges Journal of Inflammation Research stem cells mesenchymal stromal cells hscs immunosuppression inflammatory bowel disease ulcerative colitis crohn's disease |
| title | Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges |
| title_full | Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges |
| title_fullStr | Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges |
| title_full_unstemmed | Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges |
| title_short | Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges |
| title_sort | stem cell therapy in inflammatory bowel disease a review of achievements and challenges |
| topic | stem cells mesenchymal stromal cells hscs immunosuppression inflammatory bowel disease ulcerative colitis crohn's disease |
| url | https://www.dovepress.com/stem-cell-therapy-in-inflammatory-bowel-disease-a-review-of-achievemen-peer-reviewed-fulltext-article-JIR |
| work_keys_str_mv | AT tiancm stemcelltherapyininflammatoryboweldiseaseareviewofachievementsandchallenges AT zhangy stemcelltherapyininflammatoryboweldiseaseareviewofachievementsandchallenges AT yangmf stemcelltherapyininflammatoryboweldiseaseareviewofachievementsandchallenges AT xuhm stemcelltherapyininflammatoryboweldiseaseareviewofachievementsandchallenges AT zhumz stemcelltherapyininflammatoryboweldiseaseareviewofachievementsandchallenges AT yaoj stemcelltherapyininflammatoryboweldiseaseareviewofachievementsandchallenges AT wangls stemcelltherapyininflammatoryboweldiseaseareviewofachievementsandchallenges AT liangyj stemcelltherapyininflammatoryboweldiseaseareviewofachievementsandchallenges AT lidf stemcelltherapyininflammatoryboweldiseaseareviewofachievementsandchallenges |